<p>Advanced hybrid closed-loop systems represent a great technological advance in diabetes management, but the role that these new systems may have in pregnant women with T1D is still uncertain. These systems are programmed with target ranges that do not provide the aggressive control required during gestation. However, since the diffusion of AHCL is significantly increasing among T1D patients, many women become pregnant while using these systems and ask to continue off-label use of these devices during their pregnancy. We present a case of pregnancy in a 29-year-old primiparous woman with T1D since the age of 18&#xa0;years in which an AHCL system, the MiniMed™ 780G, was continuously used for the management of preconception, pregnancy, antenatal corticosteroid administration, delivery, and post-partum. We collected CGM metrics, HbA1c levels, insulin doses, and pump settings of our patient from the 6th week of gestation to post-partum. By assisting her AHCL system with some techniques, such as the use of “fake carbs” to correct high glucose levels, she achieved pregnancy-specific HbA1c and CGM glycaemic targets in all trimesters of gestation and also after the administration of corticosteroids, which were necessary for threatened preterm labor. Continuous use in the automatic mode of the 780G system may be considered in pregnant T1D women unwilling to stop AHCL therapy, provided they have been adequately informed on the limits of the system and educated on the action to take, if necessary, to overcome the aforementioned limits. In particular, the present case report shows that, in our patient, the AHCL system was safe and able to maintain adequate CGM metrics even after antenatal corticosteroid administration, a great problem for diabetologists and obstetricians, without exiting the auto mode of the system.</p>